Valuation : Scholar Rock Holding Corporation

Market Cap 6.81B 5.87B 5.52B 5.03B 9.46B 646B 9.51B 65.29B 25.41B 329B 25.56B 25B 1,090B P/E 2026 *
-17.2x
P/E 2027 * -21.7x
Enterprise Value 6.49B 5.6B 5.27B 4.8B 9.02B 616B 9.07B 62.25B 24.23B 313B 24.36B 23.84B 1,039B EV / Sales 2026 *
1,142x
EV / Sales 2027 * 43.8x
Free-Float
99.23%
Yield 2026 *
-
Yield 2027 * -
1 day-1.60%
1 week-4.05%
Current month-1.60%
1 month+18.17%
3 months+17.94%
6 months+26.25%
Current year+26.88%
1 week 55.33
Extreme 55.33
60.18
1 month 45.73
Extreme 45.73
61.76
Current year 38.75
Extreme 38.75
61.76
1 year 27.07
Extreme 27.07
61.76
3 years 5.94
Extreme 5.94
61.76
5 years 4.32
Extreme 4.325
61.76
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Operating Officer 58 2025-04-26
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 Sell

Director

-2,544 0.0022%
7/1/26 Sell

Director

-5,446 0.0047%
7/1/26 Sell

Director

-3,053 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%-4.05%+71.18%+788.55% 6.81B
-0.25%-4.10%+38.38%+92.61% 68.21B
+1.21%+0.80%+46.29%+85.32% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+1.18%-2.23%+30.87%-19.04% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.16%-5.74%-1.60%+531.81% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average -0.14%-3.94%+47.75%+261.58% 26.99B
Weighted average by Cap. +0.10%-3.25%+41.96%+173.47%

Financials

2026 *2027 *
Net sales 5.68M 4.9M 4.61M 4.2M 7.9M 539M 7.94M 54.52M 21.22M 274M 21.34M 20.88M 910M 146M 126M 119M 108M 203M 13.87B 204M 1.4B 546M 7.06B 549M 537M 23.39B
Net income -425M -367M -345M -314M -591M -40.37B -594M -4.08B -1.59B -20.53B -1.6B -1.56B -68.09B -364M -314M -295M -269M -506M -34.53B -508M -3.49B -1.36B -17.56B -1.37B -1.34B -58.24B
Net Debt -317M -274M -257M -234M -441M -30.1B -443M -3.04B -1.18B -15.31B -1.19B -1.16B -50.77B -405M -349M -329M -299M -563M -38.43B -566M -3.88B -1.51B -19.55B -1.52B -1.49B -64.81B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-09-01 US$55.89 -1.60% 763,186
26-08-31 US$56.80 -1.73% 987,264
26-08-28 US$57.80 -2.46% 809,724
26-08-27 US$59.26 -1.30% 620,744
26-08-26 US$60.04 +3.07% 2,281,289
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
55.89USD
Average target price
60.75USD
Spread / Average Target
+8.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock